UY35809A - (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos - Google Patents
(aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usosInfo
- Publication number
- UY35809A UY35809A UY0001035809A UY35809A UY35809A UY 35809 A UY35809 A UY 35809A UY 0001035809 A UY0001035809 A UY 0001035809A UY 35809 A UY35809 A UY 35809A UY 35809 A UY35809 A UY 35809A
- Authority
- UY
- Uruguay
- Prior art keywords
- bleeding
- aza
- prophylaxis
- substituted
- treatment
- Prior art date
Links
- 208000032843 Hemorrhage Diseases 0.000 abstract 2
- 208000034158 bleeding Diseases 0.000 abstract 2
- 230000000740 bleeding effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 206010007710 Cartilage injury Diseases 0.000 abstract 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 abstract 1
- 206010019860 Hereditary angioedema Diseases 0.000 abstract 1
- 208000018525 Postpartum Hemorrhage Diseases 0.000 abstract 1
- 206010049771 Shock haemorrhagic Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000001780 epistaxis Diseases 0.000 abstract 1
- 208000002085 hemarthrosis Diseases 0.000 abstract 1
- 208000031169 hemorrhagic disease Diseases 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 208000007106 menorrhagia Diseases 0.000 abstract 1
- 208000011309 nasal bleeding Diseases 0.000 abstract 1
- ZPUDLYRGRCCCIL-UHFFFAOYSA-N pyrazolo[4,3-f]quinazolin-1-one Chemical class N1=CN=CC2=C3C(=O)N=NC3=CC=C21 ZPUDLYRGRCCCIL-UHFFFAOYSA-N 0.000 abstract 1
- 230000000306 recurrent effect Effects 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 201000004595 synovitis Diseases 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente solicitud se refiere nuevas (aza)piridopirazolopirimidinonas e indazolopirimidinonas sustituidas, a los procesos para su preparación, los compuestos para usar solo o en combinaciones en un procedimiento para el tratamiento y/o la profilaxis de las enfermedades, en particular para el tratamiento y/o la profilaxis del sangrado agudo y recurrente en pacientes con o sin trastornos de sangrado hereditarios o adquiridos subyacentes, en el que el sangrado se asocia con una enfermedad o una intervención médica seleccionadas del grupo que consiste de la menorragia, hemorragia postparto, shock hemorrágico, traumatismo, cirugía, trasplante, accidente cerebrovascular, enfermedades del hígado, angioedema hereditario, sangrado nasal y sinovi tis y el daño del cartílago después de la hemartrosis.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13191642 | 2013-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY35809A true UY35809A (es) | 2015-05-29 |
Family
ID=49517406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001035809A UY35809A (es) | 2013-11-05 | 2014-10-31 | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US9598417B2 (es) |
| EP (1) | EP3066100B1 (es) |
| JP (1) | JP6431061B2 (es) |
| KR (1) | KR102312780B1 (es) |
| CN (1) | CN105683194B (es) |
| AP (1) | AP2016009175A0 (es) |
| AR (1) | AR098292A1 (es) |
| AU (1) | AU2014345771B2 (es) |
| CA (1) | CA2929378C (es) |
| CL (1) | CL2016001076A1 (es) |
| CR (1) | CR20160332A (es) |
| CU (1) | CU24361B1 (es) |
| DO (1) | DOP2016000102A (es) |
| EA (1) | EA029373B1 (es) |
| ES (1) | ES2732305T3 (es) |
| GT (1) | GT201600084A (es) |
| IL (1) | IL244645B (es) |
| MA (1) | MA39018A1 (es) |
| MX (1) | MX370419B (es) |
| PE (1) | PE20160934A1 (es) |
| PH (1) | PH12016500828A1 (es) |
| SG (1) | SG11201602133RA (es) |
| TN (1) | TN2016000161A1 (es) |
| TW (1) | TWI657089B (es) |
| UA (1) | UA117504C2 (es) |
| UY (1) | UY35809A (es) |
| WO (1) | WO2015067549A1 (es) |
| ZA (1) | ZA201602311B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY35809A (es) * | 2013-11-05 | 2015-05-29 | Bayer Pharma AG | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos |
| KR20170080647A (ko) * | 2014-11-03 | 2017-07-10 | 바이엘 파마 악티엔게젤샤프트 | 피페리디닐피라졸피리미디논 및 그의 용도 |
| WO2016173948A1 (en) * | 2015-04-30 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Indazolopyrimidinones as fibrinolysis inhibitors |
| WO2017007917A1 (en) * | 2015-07-07 | 2017-01-12 | Mast Therapeutics, Inc. | Polyoxyethylene/polyoxypropylene copolymers and fibrinolytic inhibitors, uses thereof and compositions |
| EP3318563A1 (en) | 2016-11-07 | 2018-05-09 | Sanofi | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders |
| CN110590673A (zh) * | 2019-09-02 | 2019-12-20 | 南通大学 | 一种4-氯-7-甲基-1h-吲唑及其化学合成方法 |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11654057B2 (en) | 2020-04-09 | 2023-05-23 | Bio 54, Llc | Devices for bleeding reduction and methods of making and using the same |
| TWI803177B (zh) * | 2021-02-05 | 2023-05-21 | 大陸商賽諾哈勃藥業（成都）有限公司 | 一種纖維蛋白溶酶抑制劑、其製備方法及應用 |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| CN117500799A (zh) | 2021-06-09 | 2024-02-02 | 伊莱利利公司 | 作为kras g12d抑制剂的取代的稠合吖嗪 |
| US11642324B1 (en) | 2022-03-01 | 2023-05-09 | Bio 54, Llc | Topical tranexamic acid compositions and methods of use thereof |
| CA3255475A1 (en) | 2022-04-05 | 2023-10-12 | Socpra Sciences Santé Et Humaines S.E.C. | CHYMASE INHIBITORS INTENDED FOR USE IN THE SELECTIVE RESOLUTION OF THROMBUS IN THROMBOTIC OR THROMBOEMBOLIC DISORDERS |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2192559A5 (en) * | 1972-07-17 | 1974-02-08 | Ugine Kuhlmann | Pyrimidino (1,2-b) indazole derivs - inters for dyes and pharmaceuticals, from 3-aminoindazoles and beta-ketone derivs |
| WO2006023001A1 (en) | 2004-07-30 | 2006-03-02 | Xanodyne Pharmaceuticals, Inc. | Tranexamic acid formulations |
| AR059224A1 (es) * | 2006-01-31 | 2008-03-19 | Jerini Ag | Compuestos para la inhibicion de integrinas y uso de estas |
| MX2010012793A (es) * | 2008-06-06 | 2010-12-14 | Sanofi Aventis | Derivados de urea macrociclicos y de sulfamida como inhibidores de tafia. |
| WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| US8415378B2 (en) | 2009-04-07 | 2013-04-09 | Astrazeneca Ab | Isoxazol-3(2H)-one analogs as therapeutic agents |
| WO2012047156A1 (en) * | 2010-10-04 | 2012-04-12 | Astrazeneca Ab | Isoxazol-3(2h)-one analogs as plasminogen inhibitors and their use in the treatment of fibrinolysis related diseases |
| BR112013011737A2 (pt) * | 2010-11-15 | 2016-08-09 | Univ Leuven Kath | composto, uso de um composto composição farmacêutica, e, método de tratamento ou prevenção de uma infecção por hiv |
| WO2012082947A1 (en) * | 2010-12-16 | 2012-06-21 | Irm Llc | Compounds and compositions as tgr5 agonists |
| JP5886868B2 (ja) * | 2010-12-16 | 2016-03-16 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 置換ピリミド［１，２−ｂ］インダゾールおよびＰＩ３Ｋ／ＡＫＴ経路のモジュレーターとしてのそれらの使用 |
| UY35809A (es) | 2013-11-05 | 2015-05-29 | Bayer Pharma AG | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos |
| WO2016173948A1 (en) * | 2015-04-30 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Indazolopyrimidinones as fibrinolysis inhibitors |
-
2014
- 2014-10-31 UY UY0001035809A patent/UY35809A/es not_active Application Discontinuation
- 2014-11-03 KR KR1020167014622A patent/KR102312780B1/ko not_active Expired - Fee Related
- 2014-11-03 TW TW103137976A patent/TWI657089B/zh not_active IP Right Cessation
- 2014-11-03 SG SG11201602133RA patent/SG11201602133RA/en unknown
- 2014-11-03 TN TN2016000161A patent/TN2016000161A1/en unknown
- 2014-11-03 CA CA2929378A patent/CA2929378C/en not_active Expired - Fee Related
- 2014-11-03 MX MX2016005969A patent/MX370419B/es active IP Right Grant
- 2014-11-03 EA EA201690935A patent/EA029373B1/ru not_active IP Right Cessation
- 2014-11-03 CR CR20160332A patent/CR20160332A/es unknown
- 2014-11-03 EP EP14793523.3A patent/EP3066100B1/en active Active
- 2014-11-03 CU CU2016000062A patent/CU24361B1/es unknown
- 2014-11-03 AU AU2014345771A patent/AU2014345771B2/en not_active Ceased
- 2014-11-03 PE PE2016000586A patent/PE20160934A1/es unknown
- 2014-11-03 JP JP2016527398A patent/JP6431061B2/ja not_active Expired - Fee Related
- 2014-11-03 ES ES14793523T patent/ES2732305T3/es active Active
- 2014-11-03 AP AP2016009175A patent/AP2016009175A0/en unknown
- 2014-11-03 MA MA39018A patent/MA39018A1/fr unknown
- 2014-11-03 UA UAA201605980A patent/UA117504C2/uk unknown
- 2014-11-03 WO PCT/EP2014/073529 patent/WO2015067549A1/en not_active Ceased
- 2014-11-03 CN CN201480060660.7A patent/CN105683194B/zh not_active Expired - Fee Related
- 2014-11-04 AR ARP140104130A patent/AR098292A1/es not_active Application Discontinuation
- 2014-11-05 US US14/533,915 patent/US9598417B2/en not_active Expired - Fee Related
-
2016
- 2016-03-17 IL IL244645A patent/IL244645B/en active IP Right Grant
- 2016-04-06 ZA ZA2016/02311A patent/ZA201602311B/en unknown
- 2016-05-04 PH PH12016500828A patent/PH12016500828A1/en unknown
- 2016-05-05 GT GT201600084A patent/GT201600084A/es unknown
- 2016-05-05 DO DO2016000102A patent/DOP2016000102A/es unknown
- 2016-05-05 CL CL2016001076A patent/CL2016001076A1/es unknown
-
2017
- 2017-01-26 US US15/416,651 patent/US10098883B2/en active Active
-
2018
- 2018-08-10 US US16/101,250 patent/US10668071B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY35809A (es) | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos | |
| MX382671B (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington | |
| CO2019007810A2 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| CL2019001079A1 (es) | Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina. | |
| ECSP19025350A (es) | Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi) | |
| CL2020001797A1 (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas. | |
| DOP2012000257A (es) | Derivados del acido 1-amino-2-ciclopropiletilboronico | |
| PE20170931A1 (es) | Nuevas normalizaciones y dispositivos medicos para la preparacion de plasma rico en plaquetas (prp) o concentrado de medula osea (bmc) solos o combinados con acido hialuronico | |
| UY33047A (es) | Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes | |
| CO6592044A2 (es) | Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento de cancer y enfermedadese inmunes | |
| CO6531414A2 (es) | Aptámeros del inhibidor de la vía del factor tisular y sus usos como tratamiento de trastornos hemorrágicos | |
| MX2017004761A (es) | Uso de cannabinoides en el tratamiento de enfermedades degenerativas del musculo esqueletico. | |
| BR112016021648A2 (pt) | novos compostos | |
| CL2019002079A1 (es) | Sales del inhibidor de pim quinasa; útiles en el tratamiento del cáncer. (divisional solicitud 201800611) | |
| DOP2016000308A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| MX392523B (es) | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar | |
| MX2017015292A (es) | Composicion para tratar lesiones cerebrales. | |
| UY36385A (es) | Piperidinilpirazolopirimidinonas y utilización de las mismas | |
| UY37622A (es) | Derivados de pirazol como inhibidores de bromodominio de la familia bet y su uso en aplicaciones terapéuticas | |
| CU20160139A7 (es) | Benzamidas y anilidas sustituidas en calidad de inhibidores de las vías de de señalización wnt, las composiciones y combinaciones farmacéuticas que las comprenden, y los compuestos intermediarios útiles para preparar estos compuestos | |
| MX394216B (es) | Abx196 para usarse en el tratamiento del cáncer de vejiga. | |
| CO2017003561A2 (es) | Uso del ácido neridrónico o de su sal para el tratamiento de la osteoartrosis | |
| CL2018000336A1 (es) | Composición para el tratamiento de la mucosidad en las branquias de los peces | |
| SV2016005282A (es) | Nuevos compuestos | |
| AR101944A1 (es) | Dispositivo para la compresión de la arteria renal en la nefrectomía parcial y método para emplear dicho dispositivo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20211215 |